Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. It offers a diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. The Company's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney disease, orthopedic spine conditions, and cardiovascular disorders.